| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Small fiber neuropathy (SFN) is associated with various diseases, including diabetes and transthyretin-related familial amyloid polyneuropathy (ATTR-FAP). Therefore, early and accurate diagnosis of SFN is becoming increasingly important for the early treatment of ATTR-FAP and diabetic neuropathy. In this study, I investigated which biomarker accurately predicts pathological changes in SFN. The results showed early skin denervation in ATTR-FAP, even in the presymptomatic stage of this disease. Skin denervation was correlated with disease duration and various peripheral neuropathy parameters. Our findings reveal that skin biopsy may be useful for early diagnosis and may serve as a biomarker in clinical trials for SFN.
|
